HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

KRON

Kronos Bio Inc

Last Close
Dec 13 • 04:00PM ET
0.9799
Dollar change
-0.0201
Percentage change
-2.01 		%
Healthcare • Biotechnology • USA • NASD
Peers: MDGL BPMC BHVN KNSA ARGX NBIX ONCT SRRK GLMD ONCY
 | Held by: VTI VXF IWC
Scroll to Statements
Index- P/E- EPS (ttm)-1.44 Insider Own35.92% Shs Outstand60.34M Perf Week-3.93%
Market Cap57.94M Forward P/E- EPS next Y-1.30 Insider Trans2.92% Shs Float38.67M Perf Month11.34%
Income-85.59M PEG- EPS next Q-0.29 Inst Own24.17% Short Float1.30% Perf Quarter2.94%
Sales9.86M P/S5.88 EPS this Y33.33% Inst Trans-4.56% Short Ratio2.75 Perf Half Y-9.27%
Book/sh1.84 P/B0.53 EPS next Y0.00% ROA-44.11% Short Interest0.50M Perf Year-28.99%
Cash/sh2.11 P/C0.46 EPS next 5Y- ROE-59.08% 52W Range0.69 - 1.60 Perf YTD-21.61%
Dividend Est.- P/FCF- EPS past 5Y-72.78% ROI-64.03% 52W High-38.76% Beta1.83
Dividend TTM- Quick Ratio8.32 Sales past 5Y0.00% Gross Margin81.90% 52W Low42.01% ATR (14)0.06
Dividend Ex-Date- Current Ratio8.32 EPS Y/Y TTM30.68% Oper. Margin-808.12% RSI (14)52.73 Volatility5.16% 6.14%
Employees63 Debt/Eq0.23 Sales Y/Y TTM146.48% Profit Margin-867.66% Recom3.00 Target Price1.00
Option/ShortYes / Yes LT Debt/Eq0.20 EPS Q/Q56.65% Payout- Rel Volume1.62 Prev Close1.00
Sales Surprise12.86% EPS Surprise17.12% Sales Q/Q158.45% EarningsNov 13 AMC Avg Volume182.25K Price0.98
SMA204.11% SMA504.21% SMA200-6.06% Trades Volume294,692 Change-2.01%
Date Action Analyst Rating Change Price Target Change
Nov-14-24Downgrade TD Cowen Buy → Hold
Nov-14-24Downgrade Piper Sandler Overweight → Neutral $6 → $1
Sep-14-22Initiated Berenberg Buy $12
Oct-20-21Resumed Cowen Outperform
Jun-24-21Initiated H.C. Wainwright Buy $35
Nov-03-20Initiated Piper Sandler Overweight $50
Nov-03-20Initiated Jefferies Buy $36
Nov-03-20Initiated Goldman Buy $45
Nov-03-20Initiated Cowen Outperform
Nov-28-24 11:50AM
Kronos Bio announces interim CEO and workforce cuts of 83%
(Pharmaceutical Technology)
Nov-27-24 08:59AM
Kronos Bio Shakes Up Leadership - Cuts 83% Of Workforce Amid Strategic Overhaul
(Benzinga) +10.99%
07:30AM
Kronos Bio Announces CEO Transition and Reduction in Force
(GlobeNewswire)
05:38AM
Kronos, Idorsia plan layoffs; PTC shelves ALS drug
(BioPharma Dive)
Nov-14-24 04:02PM
Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024
(GlobeNewswire)
01:24PM Loading…
01:24PM
Kronos mulls strategic alternatives after axing cancer drug development
(Pharmaceutical Technology)
Nov-13-24 05:30PM
Kronos Bio, Inc. (KRON) Reports Q3 Loss, Tops Revenue Estimates
(Zacks)
04:05PM
Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives
(GlobeNewswire)
Nov-05-24 09:00AM
Kronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple Myeloma
(GlobeNewswire)
Oct-23-24 08:55AM
Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors
(GlobeNewswire) +5.53%
Oct-09-24 08:55AM
Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors
(GlobeNewswire)
Oct-07-24 08:55AM
Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjogren's Disease
(GlobeNewswire)
08:55AM
Kronos Bio Announces Selection of Autoimmune Development Candidate for Sj gren's Disease
(GlobeNewswire)
Sep-25-24 08:55AM
Kronos Bio to Present Data at ACR Convergence 2024 to Support p300 KAT Inhibition as an Approach to Anti-Inflammatory Therapy
(GlobeNewswire) -6.96%
Sep-23-24 08:55AM
Kronos Bio Highlights Data at AACR Ovarian Cancer Research Symposium that Supports Clinical Evaluation of Istisociclib in Advanced Ovarian Cancer
(GlobeNewswire)
09:35AM Loading…
Sep-10-24 09:35AM
After Plunging -5.53% in 4 Weeks, Here's Why the Trend Might Reverse for Kronos Bio (KRON)
(Zacks)
Sep-03-24 08:55AM
Kronos Bio Announces Participation in Medical and Investor Conferences in September
(GlobeNewswire)
Aug-22-24 09:35AM
After Plunging -23.49% in 4 Weeks, Here's Why the Trend Might Reverse for Kronos Bio (KRON)
(Zacks)
Aug-08-24 04:15PM
Kronos Bio Reports Second Quarter 2024 Financial Results and Pipeline Update
(GlobeNewswire) -7.21%
Aug-06-24 10:00AM
Kronos Bio, Inc. (KRON) Expected to Beat Earnings Estimates: Should You Buy?
(Zacks)
Jul-23-24 04:15PM
Kronos Bio Announces First Patient Dosed with KB-0742 in an Expansion Cohort Focused on Platinum-Resistant High-Grade Serous Ovarian Cancer
(GlobeNewswire) +9.60%
May-23-24 05:15PM
Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
(GlobeNewswire) -22.09%
May-22-24 04:30PM
Kronos Bio to Participate in Three Upcoming Healthcare Conferences and Events
(GlobeNewswire)
May-21-24 08:15AM
Kronos Bio Appoints Deborah Knobelman, Ph.D. as Chief Operating Officer and Chief Financial Officer
(GlobeNewswire)
May-16-24 09:35AM
Down -5.63% in 4 Weeks, Here's Why Kronos Bio (KRON) Looks Ripe for a Turnaround
(Zacks)
May-09-24 10:55PM
KRON Stock Earnings: Kronos Bio Misses EPS, Beats Revenue for Q1 2024
(InvestorPlace)
05:45PM
Kronos Bio, Inc. (KRON) Reports Q1 Loss, Tops Revenue Estimates
(Zacks)
04:05PM
Kronos Bio Reports First-Quarter 2024 Financial Results
(GlobeNewswire)
Apr-24-24 04:01PM
Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
(GlobeNewswire)
Mar-27-24 12:00PM
Kronos Bio (KRON) Upgraded to Buy: What Does It Mean for the Stock?
(Zacks)
01:53PM Loading…
Mar-21-24 01:53PM
KRON Stock Earnings: Kronos Bio Beats EPS, Beats Revenue for Q4 2023
(InvestorPlace)
07:05AM
Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results
(GlobeNewswire)
Mar-07-24 04:05PM
Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash Runway
(GlobeNewswire) +7.50%
Mar-05-24 04:44PM
Kronos Bio To Present Three Posters at AACR 2024 Annual Meeting
(GlobeNewswire) +17.65%
Feb-27-24 04:05PM
Kronos Bio Announces Participation in 44th Annual Cowen Health Care Conference
(GlobeNewswire) +11.40%
Jan-25-24 08:00AM
Kronos Bio Implements New Leadership Structure to Drive Pipeline Advancement
(GlobeNewswire)
Dec-18-23 04:06PM
Kronos Bio Announces Pipeline Update and p300 KAT Inhibitor Development Candidate
(GlobeNewswire) -13.01%
Dec-04-23 08:00AM
Kronos Bio Announces Participation in H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
(GlobeNewswire)
Nov-27-23 04:05PM
Kronos Bio Announces Participation in 35th Annual Piper Sandler Healthcare Conference
(GlobeNewswire)
Nov-13-23 05:25PM
Kronos Bio, Inc. (KRON) Reports Q3 Loss, Lags Revenue Estimates
(Zacks) -5.51%
04:05PM
Kronos Bio Reports Recent Business Progress and Third-Quarter 2023 Financial Results
(GlobeNewswire)
Nov-02-23 04:05PM
Kronos Bio Announces Plan to Optimize Resource Allocation, Restructure and Contain Costs Following Positive Preliminary Clinical Data from its KB-0742 Phase 1/2 Study
(GlobeNewswire) -5.10% +15.00%
12:00PM
Kronos Bio Presents Positive Preliminary Data from the Phase 1 Dose Escalation Portion of the Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting
(GlobeNewswire)
Oct-27-23 08:00AM
Kronos Bio To Present Positive Preliminary Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting
(GlobeNewswire)
Oct-13-23 12:30PM
Kronos Bio Presents Positive Preliminary Data from Phase 1 Dose Escalation Portion of Phase 1/2 KB-0742 Study at AACR-NCI-EORTC
(GlobeNewswire) -13.70%
Oct-04-23 04:05PM
Kronos Bio To Present Interim Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at AACR-NCI-EORTC and Host Virtual Investor Event on October 13
(GlobeNewswire)
Aug-17-23 08:00AM
Kronos Bio Announces Departure of Chief Financial Officer and Head of Corporate Development
(GlobeNewswire)
Aug-08-23 05:50PM
Kronos Bio, Inc. (KRON) Reports Q2 Loss, Misses Revenue Estimates
(Zacks)
04:05PM
Kronos Bio Reports Recent Business Progress and Second-Quarter 2023 Financial Results
(GlobeNewswire)
Jul-19-23 07:27AM
With 47% ownership, Kronos Bio, Inc. (NASDAQ:KRON) has piqued the interest of institutional investors
(Simply Wall St.)
Jun-06-23 08:00AM
Kronos Bio Names Marc Besman, Ph.D., as Senior Vice President of Regulatory Affairs and Clinical Quality Assurance
(GlobeNewswire)
Jun-01-23 04:05PM
Kronos Bio Announces Participation in Upcoming Investor Conferences
(GlobeNewswire)
May-12-23 07:00AM
The past year for Kronos Bio (NASDAQ:KRON) investors has not been profitable
(Simply Wall St.)
May-10-23 05:35PM
Kronos Bio, Inc. (KRON) Reports Q1 Loss, Misses Revenue Estimates
(Zacks)
04:05PM
Kronos Bio Reports Recent Business Progress and First-Quarter 2023 Financial Results
(GlobeNewswire)
Apr-24-23 04:05PM
Kronos Bio Appoints Roger Dansey, M.D., to Board of Directors
(GlobeNewswire)
Apr-18-23 02:24PM
Kronos Bio, Inc. (NASDAQ:KRON) insider upped their holding by 11% earlier this year
(Simply Wall St.)
Apr-11-23 04:05PM
Kronos Bio Announces Changes to Board of Directors
(GlobeNewswire)
Mar-15-23 04:05PM
Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2022 Financial Results
(GlobeNewswire) -5.66%
Feb-28-23 04:05PM
Kronos Bio Announces Participation in 43rd Annual Cowen Health Care Conference
(GlobeNewswire)
Jan-09-23 09:25AM
Deals, data kick off biotech's big JPM Week
(American City Business Journals) +15.12%
08:23AM
Kronos Bios stock rallies after announcing drug-discovery deal with Roche
(MarketWatch)
07:00AM
Kronos Bio Announces Discovery Collaboration with Genentech to Advance Novel Therapies Against Transcriptional Targets in Oncology
(GlobeNewswire)
Dec-20-22 10:28AM
We're Keeping An Eye On Kronos Bio's (NASDAQ:KRON) Cash Burn Rate
(Simply Wall St.) -5.19%
Dec-12-22 09:35AM
Here's Why Kronos Bio, Inc. (KRON) is Poised for a Turnaround After Losing 31% in 4 Weeks
(Zacks) +10.23%
Dec-11-22 10:00AM
Kronos Bio Presents Preclinical Data Supporting Anti-Leukemic Activity of Lanraplenib in Combination with Multiple Targeted Agents in Acute Myeloid Leukemia (AML) Preclinical Models at American Society of Hematology Meeting
(GlobeNewswire)
Dec-07-22 04:05PM
Kronos Bio Announces Selection of Recommended Phase 2 Dose for its Oral CDK9 Inhibitor, KB-0742, After Reaching Target Engagement Goal with Acceptable Safety Profile in Ongoing Phase 1/2 Clinical Trial
(GlobeNewswire)
Nov-22-22 04:05PM
Kronos Bio Announces Participation in Upcoming Investor Conferences
(GlobeNewswire)
09:35AM
Here's Why Kronos Bio, Inc. (KRON) is Poised for a Turnaround After Losing 23.8% in 4 Weeks
(Zacks)
Nov-09-22 12:04PM
Insiders might want to re-evaluate their US$2.4m stock purchase as Kronos Bio, Inc. (NASDAQ:KRON) drops to US$145m
(Simply Wall St.) -9.38%
Nov-08-22 04:10PM
Kronos Bio Reports Recent Business Progress and Third-Quarter 2022 Financial Results
(GlobeNewswire)
04:05PM
Kronos Bio Announces Prioritization of Clinical Portfolio to Focus on Lanraplenib and KB-0742
(GlobeNewswire)
Oct-12-22 04:04AM
Kronos Bio to Present Preclinical Data for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers, in Pediatric Cancer Models in Poster Presentation at EORTC-NCI-AACR 2022
(GlobeNewswire)
Sep-06-22 04:05PM
Kronos Bio Announces Participation in H.C. Wainwright 24th Annual Global Investment Conference
(GlobeNewswire) +10.95%
Aug-22-22 11:33AM
Kronos Bio Starts Dosing In Early-Stage Leukemia Study With Next-Gen SYK Inhibitor
(Benzinga) -6.10%
08:00AM
Kronos Bio Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Lanraplenib in Combination with Gilteritinib in Acute Myeloid Leukemia
(GlobeNewswire)
Aug-16-22 04:05PM
Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio's Investigational Compound Being Developed for Patients with AML
(PR Newswire) -6.01% -6.39%
Aug-09-22 09:55AM
Can Kronos Bio, Inc. (KRON) Climb 312% to Reach the Level Wall Street Analysts Expect?
(Zacks) -9.47%
Aug-04-22 04:05PM
Kronos Bio Reports Recent Business Progress and Second-Quarter 2022 Financial Results
(GlobeNewswire)
Jul-25-22 08:48AM
7 Nasdaq Stocks to Buy on the Dip
(InvestorPlace)
Jul-10-22 10:27AM
We're Keeping An Eye On Kronos Bio's (NASDAQ:KRON) Cash Burn Rate
(Simply Wall St.)
Jul-08-22 12:00PM
Kronos Bio, Inc. (KRON) Upgraded to Buy: Here's What You Should Know
(Zacks)
Jun-10-22 03:04AM
Kronos Bio Continues to Advance Investigational SYK Inhibitors Entospletinib and Lanraplenib with New Preclinical Data at EHA2022 Congress
(GlobeNewswire) -13.07%
Jun-01-22 04:05PM
Kronos Bio Announces Participation in Upcoming Investor Conferences
(GlobeNewswire) -7.26%
May-22-22 08:04AM
Norbert Bischofberger Is The President of Kronos Bio, Inc. (NASDAQ:KRON) And They Just Picked Up 11% More Shares
(Simply Wall St.)
May-17-22 07:00AM
Kronos Bio Announces Participation in H.C. Wainwright Global Investment Conference
(GlobeNewswire) +8.54%
May-12-22 10:23AM
Kronos Bios Investigational SYK Inhibitors Entospletinib and Lanraplenib to be Featured in Four Poster Presentations at EHA2022 Congress
(GlobeNewswire)
May-06-22 12:23PM
Could The Kronos Bio, Inc. (NASDAQ:KRON) Ownership Structure Tell Us Something Useful?
(Simply Wall St.) -7.01%
May-04-22 04:05PM
Kronos Bio Reports Recent Business Progress and First-Quarter 2022 Financial Results
(GlobeNewswire) -5.80%
Apr-08-22 01:07PM
Kronos Bio Presents Preclinical Data on Oral CDK9 Inhibitor KB-0742, Providing Additional Evidence of Potential Efficacy in MYC-Amplified and Transcriptionally Addicted Tumors at AACR
(GlobeNewswire)
Mar-08-22 05:08PM
Kronos Bios Investigational CDK9 Inhibitor KB-0742 to be Featured in Four Preclinical Poster Presentations at American Association for Cancer Research Annual Meeting 2022
(GlobeNewswire) +8.51%
Mar-01-22 07:00AM
Kronos Bio Announces Participation in Cowen 42nd Annual Health Care Conference
(GlobeNewswire)
Feb-24-22 04:05PM
Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2021 Financial Results
(GlobeNewswire) +6.41%
Feb-01-22 04:05PM
Kronos Bio Announces Appointment of Elizabeth Olek as Senior Vice President of Clinical Development
(GlobeNewswire) -10.79%
Jan-31-22 01:45PM
We're Not Very Worried About Kronos Bio's (NASDAQ:KRON) Cash Burn Rate
(Simply Wall St.)
Dec-17-21 08:00AM
Omega Funds Closes Oversubscribed $650 Million Fund VII to Invest in Transformative Life Science Companies
(PR Newswire) +9.14%
Dec-09-21 10:15AM
Kronos Bio Inc (KRON) President & CEO Norbert W Bischofberger Bought $173,564 of Shares
(GuruFocus.com)
Dec-06-21 07:00AM
Kronos Bio Announces First Patient Dosed in AGILITY Phase 3 Clinical Trial of Entospletinib in Patients With Newly Diagnosed NPM1-mutated Acute Myeloid Leukemia
(GlobeNewswire)
Nov-29-21 07:00AM
Kronos Bio Announces Positive Data from Ongoing Phase 1/2 Trial of Oral CDK9 Inhibitor KB-0742
(GlobeNewswire) -5.78%
Nov-24-21 07:00AM
Kronos Bio Announces Participation in Upcoming Investor Conferences
(GlobeNewswire)
Kronos Bio, Inc. is a clinical development biopharmaceutical company. It engages in the business of developing therapeutics that target dysregulated transcription that causes cancer and other serious diseases. The company was founded by Arie S. Belldegrun, Joshua A. Kazam, David M. Tanen, and Christopher Wilfong on June 2, 2017 and is headquartered in San Mateo, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BISCHOFBERGER NORBERT WPRESIDENT & CEOJun 27 '24Buy1.17410,848478,84310,597,468Jul 01 08:27 PM
BISCHOFBERGER NORBERT WPRESIDENT & CEOJun 28 '24Buy1.25204,670254,95710,802,138Jul 01 08:27 PM
BISCHOFBERGER NORBERT WPRESIDENT & CEOJun 10 '24Buy0.881,378,9011,208,4695,749,395Jun 12 07:23 PM
BISCHOFBERGER NORBERT WPRESIDENT & CEOJun 12 '24Buy1.24881,9131,096,0417,375,616Jun 12 07:23 PM
BISCHOFBERGER NORBERT WPRESIDENT & CEOJun 11 '24Buy1.09744,308814,5716,493,703Jun 12 07:23 PM
Olek Elizabeth ASR VP, CLINICAL SCIENCEFeb 21 '24Sale1.057,3687,765193,275Feb 23 08:12 PM
Lin Charles YSR VP, RESEARCH & DEVELOPMENTFeb 21 '24Sale1.0512,03612,685234,603Feb 23 08:07 PM
Frisbee AllisonSR VP, CORP OPERATIONS & LEGALFeb 21 '24Sale1.0512,10512,757204,510Feb 23 08:04 PM
Dinsmore ChristopherChief Scientific OfficerJan 04 '24Sale1.187,3668,718260,969Jan 05 06:30 PM
DiMartino JorgeChief Medical Officer & VPJan 04 '24Sale1.1812,00914,214315,246Jan 05 06:27 PM
Kosacz BarbaraCOO & General CounselJan 04 '24Sale1.1810,67612,636928,966Jan 05 06:26 PM
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • help • privacy • do not sell my data
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.